Michael S Cookson1, Sam S Chang2, Christine Lihou3, Thomas Li4, Samira Q Harper3, Zhihui Lang3, Ronald F Tutrone5. 1. Department of Urologic Surgery, Vanderbilt University Medical Center, MCN A-1302, Nashville, TN 37027, USA. 2. Vanderbilt University Medical Center, Nashville, TN, USA. 3. Formerly of Endo Pharmaceuticals Inc., Malvern, PA, USA. 4. Endo Pharmaceuticals Inc., Malvern, PA, USA. 5. Chesapeake Urology Research Associates, Towson, MD, USA.
Abstract
OBJECTIVES: The objective was to conduct a US multicenter, retrospective medical record study examining the effectiveness, safety, and patterns of use of valrubicin for treatment of nonmuscle-invasive bladder cancer (NMIBC) by clinicians since the 2009 reintroduction of valrubicin. METHODS: Patients ≥ 18 years with NMIBC who received had one or more instillations of valrubicin (October 2009- September 2011) were eligible. The primary endpoint was event-free survival (EFS). Safety and tolerability were also assessed. RESULTS: The medical records of 113 patients met the inclusion criteria; 100 patients (88.5%) completed valrubicin treatment. The median age was 75 years (range 42-95 years). The median NMIBC duration was 31 months since diagnosis: 51.3% (58/113) had carcinoma in situ (CIS) alone, and 31.9% (36/113) had unspecified NMIBC. Most patients, 94.7% (107/113), had more than three valrubicin instillations and 70.8% (80/113) completed a full course. The EFS rate (95% confidence interval) was 51.6% (40.9-61.3%), 30.4% (20.4-41.1%), and 16.4% (7.9-27.5%) at 3, 6, and 12 months, respectively. Median time to an event was 3.5 (2.5-4.0) months after the first valrubicin instillation. Local adverse reactions (LARs) were experienced by 49.6% (56/113) of patients; most LARs were mild (93.6%). The most frequent LARs were hematuria, pollakiuria, micturition urgency, bladder spasm, and dysuria. In total, 4.4% (5/113) of patients discontinued valrubicin because of adverse events or LARs. CONCLUSIONS: Data from the present retrospective study are consistent with previous prospective clinical trials that demonstrated valrubicin effectiveness and tolerability for select patients with CIS, before considering cystectomy. Additional prospective studies are warranted to evaluate valrubicin safety and efficacy in the broader patient population with NMIBC.
OBJECTIVES: The objective was to conduct a US multicenter, retrospective medical record study examining the effectiveness, safety, and patterns of use of valrubicin for treatment of nonmuscle-invasive bladder cancer (NMIBC) by clinicians since the 2009 reintroduction of valrubicin. METHODS:Patients ≥ 18 years with NMIBC who received had one or more instillations of valrubicin (October 2009- September 2011) were eligible. The primary endpoint was event-free survival (EFS). Safety and tolerability were also assessed. RESULTS: The medical records of 113 patients met the inclusion criteria; 100 patients (88.5%) completed valrubicin treatment. The median age was 75 years (range 42-95 years). The median NMIBC duration was 31 months since diagnosis: 51.3% (58/113) had carcinoma in situ (CIS) alone, and 31.9% (36/113) had unspecified NMIBC. Most patients, 94.7% (107/113), had more than three valrubicin instillations and 70.8% (80/113) completed a full course. The EFS rate (95% confidence interval) was 51.6% (40.9-61.3%), 30.4% (20.4-41.1%), and 16.4% (7.9-27.5%) at 3, 6, and 12 months, respectively. Median time to an event was 3.5 (2.5-4.0) months after the first valrubicin instillation. Local adverse reactions (LARs) were experienced by 49.6% (56/113) of patients; most LARs were mild (93.6%). The most frequent LARs were hematuria, pollakiuria, micturition urgency, bladder spasm, and dysuria. In total, 4.4% (5/113) of patients discontinued valrubicin because of adverse events or LARs. CONCLUSIONS: Data from the present retrospective study are consistent with previous prospective clinical trials that demonstrated valrubicin effectiveness and tolerability for select patients with CIS, before considering cystectomy. Additional prospective studies are warranted to evaluate valrubicin safety and efficacy in the broader patient population with NMIBC.
Authors: M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer Journal: J Urol Date: 2007-12 Impact factor: 7.450
Authors: Maurizio Brausi; J Alfred Witjes; Donald Lamm; Raj Persad; Joan Palou; Marc Colombel; Roger Buckley; Mark Soloway; Hideyuki Akaza; Andreas Böhle Journal: J Urol Date: 2011-10-19 Impact factor: 7.450
Authors: A L Patterson; R E Greenberg; L Weems; R Bahnson; Z Wajsman; M Israel; T Sweatman; D Webber; J Gulfo Journal: Urology Date: 2000-08-01 Impact factor: 2.649
Authors: R E Greenberg; R R Bahnson; D Wood; S J Childs; C Bellingham; M Edson; M H Bamberger; G D Steinberg; M Israel; T Sweatman; B Giantonio; P J O'Dwyer Journal: Urology Date: 1997-03 Impact factor: 2.649
Authors: Robert S Svatek; Mark B Fisher; Surena F Matin; Ashish M Kamat; H Barton Grossman; Graciela M Nogueras-González; Diana L Urbauer; Kathleen A Kennedy; Colin P Dinney Journal: J Urol Date: 2010-01-18 Impact factor: 7.450
Authors: Jeffrey M Ignatoff; Yu-Hui Chen; Richard Evan Greenberg; Julio M Pow-Sang; Edward M Messing; George Wilding Journal: Urol Oncol Date: 2008-07-17 Impact factor: 3.498
Authors: Andrey E Shchekotikhin; Lyubov G Dezhenkova; Vladimir B Tsvetkov; Yuri N Luzikov; Yulia L Volodina; Victor V Tatarskiy; Anastasia A Kalinina; Michael I Treshalin; Helen M Treshalina; Vladimir I Romanenko; Dmitry N Kaluzhny; Michael Kubbutat; Dominique Schols; Yves Pommier; Alexander A Shtil; Maria N Preobrazhenskaya Journal: Eur J Med Chem Date: 2016-02-04 Impact factor: 6.514
Authors: Andres F Correa; Katherine Theisen; Matthew Ferroni; Jodi K Maranchie; Ronald Hrebinko; Benjamin J Davies; Jeffrey R Gingrich Journal: Adv Urol Date: 2015-10-13